Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $140.00 at Wells Fargo & Company
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...
Fierce Pharma4d
Gilead sets aside $200M for potential settlement over HIV drug speaker program
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
5 Big Biopharmaceutical Stocks That Are Finding Favor
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
Why Gilead Sciences Remains A Buy After A 40% Rally
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...
Gilead price target raised to $126 from $116 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...
The Japan Times3d
Gilead's Japan head says nation can be among first to end HIV epidemic
The pharmaceutical powerhouse has two drugs that disrupt the transmission of the virus, one of which has been approved for ...
Bank of America Securities Remains a Buy on Gilead Sciences (GILD)
In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...
Harnessing innovation to accelerate progress and end the HIV epidemic by 2030
Innovation in HIV care and prevention is transforming the fight, but there is more to be done in order to meet the UNAIDS targets of ending the HIV epidemic by 2030 ...